SEI Investments’s Ovid Therapeutics OVID Stock Holding History

SEI Investments’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$525K	Buy	210,671 +13,986	+7%	+$36.6K	﹤0.01%	2617
2026 Q2	$529K	Sell	196,685 -132,239	-40%	-$341K	﹤0.01%	2613
2026 Q1	$730K	Buy	+328,924	New	+$588K	﹤0.01%	2511
2023 Q1	–	Sell	-33,832	Closed	-$62.9K	–	2722
2022 Q4	$62.9K	Hold	33,832	–	–	﹤0.01%	2476
2022 Q3	$62K	Sell	33,832 -39,156	-54%	-$81.9K	﹤0.01%	2608
2022 Q2	$157K	Sell	72,988 -46,366	-39%	-$112K	﹤0.01%	2515
2022 Q1	$375K	Hold	119,354	–	–	﹤0.01%	2211
2021 Q4	$383K	Buy	119,354 +38,657	+48%	+$132K	﹤0.01%	2249
2021 Q3	$271K	Hold	80,697	–	–	﹤0.01%	2348
2021 Q2	$316K	Buy	+80,697	New	+$318K	﹤0.01%	2290
2018 Q3	–	Sell	-97	Closed	-$1K	–	3151
2018 Q2	$1K	Buy	+97	New	+$833	﹤0.01%	3497

Other funds holding OVID

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

SEI Investments's OVID Position: Q3 2026 in Review

SEI Investments increased its Ovid Therapeutics (OVID) stake by 7.1% in Q3 2026, buying an estimated $36.6K and bringing the position to 210,671 shares worth $525K. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

SEI Investments first reported a position in OVID in Q2 2018 and has held it in 11 quarters since. The position peaked at $730K in Q1 2026. 47 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

SEI Investments held 210,671 shares of Ovid Therapeutics worth $525K as of Q3 2026.
SEI Investments bought 13,986 Ovid Therapeutics shares in Q3 2026, an estimated $36.6K.
Ovid Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #2617 holding.
SEI Investments first reported a position in Ovid Therapeutics in Q2 2018 and has held it in 11 quarters since.
SEI Investments's Ovid Therapeutics position peaked at $730K in Q1 2026.
47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.